Medical equipment developer Baxter has obtained the European CE-Mark for its new Evo IQ Infusion System designed to minimise the risk of error and enable the use of drug libraries.
Baxter is currently planning to market the device in the UK, Ireland and New Zealand. It has also secured regulatory approval from the Therapeutic Goods Administration (TGA) in Australia.
Initially, the device will include a volumetric infusion pump and the company is planning to add a pipeline of complementary technology in the future.
The additional features will include more pumps and set offerings to allow expansion and upgrade of the Evo IQ platform by healthcare facilities.
Evo IQ comes with advanced drug library and dose error reduction software to improve patient safety and facilitate intuitive clinical workflows in order to optimise clinician efficiency.
The company also included its One Set technology to enable easy switch between gravity and pump applications without the need for changing sets, and help minimise chances of touch contamination.
Baxter Medication Delivery general manager David Ferguson said: “With the Evo IQ Infusion System, Baxter is extending its leading-edge infusion systems technology to help increase drug library compliance and protect patient infusions in the UK, Ireland, Australia and New Zealand.
“The Evo IQ Infusion System provides healthcare facilities with access to Baxter’s proven infusion safety technology in an adaptable system that can grow with their needs.”
The device is designed to support drug libraries in order to aid clinicians in identifying infusion pump programming errors, curate a list of medications and fluids, and set required dose ranges.
In case the programming goes beyond the specified limits, the system will send alerts prior to administration or prevent the delivery of the medication in certain cases.